Assessing the efficacy of high-dose rifampicin plus albendazole against onchocerciasis
PLOS Neglected Tropical Diseases · 12.08.2026 · 20 (8) · e0014594
DOI: 10.1371/journal.pntd.0014594 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 12.08.2026. Verfasst von Monica Ahiadorme und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Microbiology, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. Hauptthemen laut MEDLINE: Rifampin, Albendazole, Onchocerciasis, Anthelmintics. Die Arbeit nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European and Developing Countries Clinical Trials Partnership, Bundesministerium für Bildung und Forschung.
Abstract (Originalsprache)
Background
Onchocerciasis, also known as river blindness, remains a public health challenge in tropical regions. Despite significant gains through mass drug administration (MDA) with ivermectin, the infection remains persistent in many endemic foci. While the disease burden has reduced, elimination may require alternative strategies, including macrofilaricidal therapies. Rifampicin (RIF) has demonstrated strong anti- Wolbachia activity in vitro and in animal models, but its clinical efficacy in humans remains uncertain.
Methods
We conducted a phase II randomised, controlled trial in Ghana to evaluate the safety and efficacy of high-dose RIF (35 mg/kg/day) combined with albendazole (ALB, 400 mg/day) as an alternative treatment for onchocerciasis. The study randomised 120 infected participants into one of four arms: RIF + ALB for 14 days (TA1), RIF + ALB for 7 days (TA2), ALB alone for 14 days (TA3), and a No Treatment control group (TA4). Treatment efficacy, including Wolbachia and microfilariae (MF) depletion, adult worm vitality and embryogenesis were assessed following treatment at 4-, 18-, and 20-months.
Results
High-dose RIF + ALB was safe and well-tolerated, associated with only mild, transient adverse events. Treatment with RIF + ALB for 14 days reduced Wolbachia load in skin MF at 4 months (47.9%; p = 0.018 ). ALB monotherapy showed sustained reductions in skin microfilarial densities at the 18- and 20-month time points ( p < 0.05 ). However, no macrofilaricidal effect or sustained Wolbachia depletion in adult worms was observed in any group.
Conclusion
High-dose RIF + ALB is safe with limited macrofilaricidal efficacy in clinical settings, contrasting with the superiority observed from preclinical trials. ALB alone shows promise as an alternative microfilaricidal treatment to ivermectin or as a complementary regimen. The lack of sustained efficacy of RIF as an anti- Wolbachia regimen may reflect suboptimal dosing, highlighting the need for further optimisation of RIF-based regimens for onchocerciasis treatment.
Trial registration
PACTR202009704006025 ( https://pactr.samrc.ac.za/Search.aspx ). Date of trial registration: September 9, 2020
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Microbiology, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
- Kumasi Centre for Collaborative Research in Tropical Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
- Department of Basic Sciences, School of Basic and Biomedical Sciences, University of Health and Allied Sciences, Ho, Ghana.
- University of Bonn, University Hospital Bonn, Institute for Medical Microbiology, Immunology and Parasitology, Bonn, Germany.
- German Centre for Infection Research (DZIF), partner site, Bonn-Cologne, Germany.
- University of Bonn, University Hospital Bonn, Institute for Medical Biometry, Informatics and Epidemiology, Bonn, Germany.
ORCID-Profile: Alexander Yaw Debrah
Förderung
- European and Developing Countries Clinical Trials Partnership
- Bundesministerium für Bildung und Forschung
Zitieren
APA
Ahiadorme, M., Klarmann-Schulz, U., Dubben, B., Nadal, J., Korir, P. J., Pfarr, K., Kuehlwein, J. M., Lenz-Plet, F., Ricchiuto, A., Kutu, E. D., Mensah, D. A., Opoku, V. S., Boateng, J., Opoku, J., Osei-Mensah, J., Gyasi, C., Obeng, P., Kuutiero, E. K., Obeng, M. A., …, & Debrah, A. Y. (2026). Assessing the efficacy of high-dose rifampicin plus albendazole against onchocerciasis. PLOS Neglected Tropical Diseases, 20(8), e0014594. https://doi.org/10.1371/journal.pntd.0014594
Vancouver
Ahiadorme M, Klarmann-Schulz U, Dubben B, Nadal J, Korir PJ, Pfarr K, et al. Assessing the efficacy of high-dose rifampicin plus albendazole against onchocerciasis. PLOS Neglected Tropical Diseases. 2026;20(8):e0014594. doi:10.1371/journal.pntd.0014594
BibTeX
@article{Ahiadorme2026,
author = {Ahiadorme, Monica and Klarmann-Schulz, Ute and Dubben, Bettina and Nadal, Jennifer and Korir, Patricia Jebett and Pfarr, Kenneth and Kuehlwein, Janina M and Lenz-Plet, Franziska and Ricchiuto, Arcangelo and Kutu, Emmanuel Donawobuge and Mensah, Derrick Adu and Opoku, Vera Serwaa and Boateng, John and Opoku, John and Osei-Mensah, Jubin and Gyasi, Charles and Obeng, Prince and Kuutiero, Eunice Kyaakyile and Obeng, Michael Agyemang and Emikpe, Benjamin and Rahamani, Abu Abudu and Atisu, Prince Dennis and Ayisi-Boateng, Nana Kwame and Kontoh, Derrick Boateng and Twumasi-Ankrah, Sampson and Hoerauf, Achim and Debrah, Linda Batsa and Debrah, Alexander Yaw},
title = {Assessing the efficacy of high-dose rifampicin plus albendazole against onchocerciasis},
journal = {PLOS Neglected Tropical Diseases},
year = {2026},
volume = {20},
number = {8},
pages = {e0014594},
doi = {10.1371/journal.pntd.0014594}
}
EUVIMED